泰恩康：控股股东、实际控制人郑汉杰解除质押350万股，质押400万股

Group 1 - The company, 泰恩康, announced the receipt of a notification from its controlling shareholder, 郑汉杰, regarding the handling of share pledges, including the release of 3.5 million shares and the pledge of 4 million shares [1] - For the fiscal year 2024, the company's revenue composition is as follows: 61.1% from pharmaceutical agency, 37.28% from pharmaceutical manufacturing, 1.51% from pharmaceutical technology services, and 0.12% from other businesses [1] - As of the report date, the market capitalization of 泰恩康 is 14.3 billion yuan [1]